Evidence map›Paper›PMID 42439936›Full record

ReviewOrthopadie (Heidelberg, Germany)2026

[Surgical treatment options for soft tissue sarcomas : Indications, diagnostics, techniques, and limitations].

Silvan Wittenberg, Anne Flörcken, Franziska Borchert, Pirus Ghadjar, Annika Strönisch, Tomasz Dziodzio, Frederik Maximilian Schäfer, Sanas Mirhoseiny, Armin Jarosch, Daniel Rau

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Orthopadie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Silvan WittenbergCentrum für Muskuloskeletale Chirurgie, Gliedkörperschaft der Freien Universität Berlin und der Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Deutschland. Silvan.Wittenberg@charite.de.
Anne FlörckenMedizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Gliedkörperschaft der Freien Universität Berlin und der Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Berlin, Deutschland.
Franziska BorchertMedizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Gliedkörperschaft der Freien Universität Berlin und der Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Berlin, Deutschland.
Pirus GhadjarKlinik für Radioonkologie und Strahlentherapie, Gliedkörperschaft der Freien Universität Berlin und der Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Berlin, Deutschland.
Annika StrönischMedizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Gliedkörperschaft der Freien Universität Berlin und der Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Berlin, Deutschland.
Tomasz DziodzioChirurgische Klinik, Gliedkörperschaft der Freien Universität Berlin und der Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Berlin, Deutschland.
Frederik Maximilian SchäferKlinik für Radiologie, Gliedkörperschaft der Freien Universität Berlin und der Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Berlin, Deutschland.
Sanas MirhoseinyPlastische und Rekonstruktive Chirurgie, Chirurgische Klinik, Gliedkörperschaft der Freien Universität Berlin und der Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Berlin, Deutschland.
Armin JaroschInstitut für Pathologie, Gliedkörperschaft der Freien Universität Berlin und der Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Berlin, Deutschland.
Daniel RauCentrum für Muskuloskeletale Chirurgie, Gliedkörperschaft der Freien Universität Berlin und der Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Soft tissue sarcomas are rare, heterogeneous mesenchymal malignancies with variable prognosis. Management requires structured diagnostics and interdisciplinary treatment at specialized centers. Imaging with MRI or CT and a carefully planned biopsy are essential for diagnosis and surgical strategy. In curative settings, complete R0 resection is the primary goal, while metastatic disease requires an individualized approach. Low-grade sarcomas are often treated with marginal resection, whereas high-grade tumors require multimodal therapy including neoadjuvant treatment, wide resection, and adjuvant radiotherapy. Surgical margins depend mainly on anatomical barriers. Functional outcomes and reconstruction are key considerations. Limb preservation is usually achievable, while amputation is rarely necessary.

Indexed as

SarcomaAmputation, SurgicalBiopsyCombined Modality TherapyHumansMagnetic Resonance ImagingNeoadjuvant TherapyPrognosisRadiotherapy, AdjuvantAmputationBiopsyNeoadjuvant therapyNeoplasmsPrognosis

Identifiers

PMID42439936

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.